Oric Pharmaceuticals, Inc. $ORIC Shares Purchased by Invesco Ltd.

Invesco Ltd. increased its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 68.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,419 shares of the company’s stock after purchasing an additional 16,461 shares during the quarter. Invesco Ltd. owned 0.06% of Oric Pharmaceuticals worth $226,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Oric Pharmaceuticals by 16.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company’s stock worth $5,788,000 after buying an additional 103,237 shares in the last quarter. Northern Trust Corp increased its position in Oric Pharmaceuticals by 5.3% during the fourth quarter. Northern Trust Corp now owns 553,993 shares of the company’s stock worth $4,471,000 after buying an additional 28,079 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Oric Pharmaceuticals during the fourth quarter worth $71,000. Bank of America Corp DE increased its position in Oric Pharmaceuticals by 34.0% during the fourth quarter. Bank of America Corp DE now owns 112,520 shares of the company’s stock worth $908,000 after buying an additional 28,570 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Oric Pharmaceuticals by 48.4% during the fourth quarter. Deutsche Bank AG now owns 57,437 shares of the company’s stock worth $464,000 after buying an additional 18,745 shares in the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 32,466 shares of the business’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the completion of the sale, the chief financial officer owned 68,317 shares of the company’s stock, valued at approximately $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Angie You purchased 26,597 shares of the stock in a transaction on Friday, June 20th. The shares were purchased at an average cost of $9.39 per share, with a total value of $249,745.83. Following the transaction, the director owned 26,597 shares of the company’s stock, valued at $249,745.83. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 37,100 shares of company stock valued at $387,263. 5.55% of the stock is owned by company insiders.

Oric Pharmaceuticals Trading Up 1.0%

ORIC stock opened at $10.88 on Monday. The stock has a 50-day moving average price of $10.41 and a two-hundred day moving average price of $8.09. Oric Pharmaceuticals, Inc. has a 12-month low of $3.90 and a 12-month high of $14.67. The company has a market cap of $1.06 billion, a PE ratio of -5.76 and a beta of 1.63.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). Equities analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ORIC shares. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a “buy” rating and a $15.00 price target for the company. Zacks Research raised Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday, August 12th. JPMorgan Chase & Co. dropped their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, August 14th. Finally, Guggenheim started coverage on Oric Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $18.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.29.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.